FutureChem
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
FutureChem develops radiopharmaceuticals, medicines that attach a radioactive isotope to a targeting molecule so doctors can both image and treat diseases such as prostate cancer, Alzheimer's disease, and brain tumours.
Its products are used in nuclear-medicine departments at hospitals and clinics. Listed on KOSDAQ, Korea's tech and small-cap board, the company holds approved diagnostic drugs as well as a pipeline of therapeutic candidates, with its commercial revenue anchored in its approved imaging agents while later-stage treatment drugs remain in development.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates its own proprietary automated synthesis device, branded sCUBE®, which it developed in-house to manufacture radiopharmaceuticals under pharmaceutical-grade production standards.
FutureChem in five facts
What does FutureChem do?
FutureChem develops radiopharmaceuticals, medicines that attach a radioactive isotope to a targeting molecule so doctors can both image and treat diseases such as prostate cancer, Alzheimer's disease, and brain tumours.
Where is FutureChem listed and in which sector?
FutureChem (Korean name: 퓨쳐켐) trades under KRX code 220100 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is FutureChem?
Its market capitalisation was US$166M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were FutureChem's latest annual revenue and operating profit?
For fiscal year 2025, FutureChem reported revenue of US$14.1M, an operating loss of US$5.9M and net income of US$32.8K, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was up 8.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Sep 21
- Report on securities held by executives/major shareholdersSep 21
- Report on securities held by executives/major shareholdersSep 21
- Report on securities held by executives/major shareholdersSep 21
- Report on securities held by executives/major shareholdersSep 21
- Ex-rights (bonus issue)Capital raise · Sep 16
- Report on large shareholdings (5% rule) (standard)Sep 16
- Report on securities held by executives/major shareholdersSep 16
- Report on securities held by executives/major shareholdersSep 16
- Report on securities held by executives/major shareholdersSep 16
- Report on securities held by executives/major shareholdersSep 16
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Sep 14
- Securities issuance results (voluntary)Sep 11
- Securities issuance reportSep 11
- [Amended] Subscription results of rights offering or equity-linked bonds (voluntary)Capital raise · Sep 7 · 2 versions
- Rights offering: final issue price set
FutureChem finalized the issue price for its rights offering at US$4.30 per share for 3,389,380 registered common shares (par value US$0.36), versus a first-round price of US$4.79, with the final price determined on 2026-08-31.
Capital raise · Sep 1 - [Amended] ProspectusSep 1
- [Terms finalized] Securities registration statement (equity)Sep 1
- [Amended] Material event report (paid-in and bonus issue)
FutureChem updated the terms of a new share issuance to raise US$16.2M, about 11.9% of its market value.
Capital raise · Sep 1 · 4 versions - Ex-rights (rights offering)
FutureChem common shares (code A220100) will trade ex-rights from July 15, 2026 at a base price of US$5.69 in connection with a rights offering.
Capital raise · Jul 14 - Rights offering: round 1 issue price set
FutureChem set the first (preliminary) issue price for its rights offering of 3,389,830 common shares at US$4.42 per share as of July 13, 2026; the final issue price will be announced on September 1, 2026.
Capital raise · Jul 14 - Trading suspension (bonus issue)Capital raise · May 29
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 13
- [Attachment amended] Material event report (decision to redeem own convertible bonds early)Capital raise · Mar 13